Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Bausch + Lomb Corporation ( (BLCO) ) just unveiled an update.
Bausch + Lomb announced the publication of a study in Clinical Ophthalmology demonstrating the effectiveness of XIIDRA, a prescription eye drop, in alleviating end-of-day eye dryness and discomfort for contact lens wearers. The study showed significant improvements in symptoms as early as two weeks, with continued use resulting in further symptom relief and increased comfortable contact lens wear time. These findings suggest XIIDRA as a viable alternative for those who do not find relief with over-the-counter options, potentially enhancing the company’s position in the eye care market.
The most recent analyst rating on (BLCO) stock is a Hold with a $16.00 price target. To see the full list of analyst forecasts on Bausch + Lomb Corporation stock, see the BLCO Stock Forecast page.
Spark’s Take on BLCO Stock
According to Spark, TipRanks’ AI Analyst, BLCO is a Neutral.
Bausch + Lomb’s overall stock score reflects a mixed financial performance with ongoing profitability challenges. Positive technical indicators and proactive corporate events provide some optimism, but valuation concerns and neutral earnings sentiment weigh on the score.
To see Spark’s full report on BLCO stock, click here.
More about Bausch + Lomb Corporation
Bausch + Lomb Corporation is a leading global eye health company focused on helping people see better to live better. The company specializes in eye health products, including prescription eye drops and contact lenses, with a market focus on addressing eye health issues such as dry eye disease.
Average Trading Volume: 789,517
Technical Sentiment Signal: Buy
Current Market Cap: $5.31B
See more data about BLCO stock on TipRanks’ Stock Analysis page.